Through the work of Wang and colleagues, there is now a better understanding of the role of CD300ld as a key immune suppressor on PMN‐MDSCs, contributing to tumor immune evasion and offering a molecular basis for its targeting in cancer immunotherapy strategies.1, 2. Here, CD300LD is linked to neoplasm.